US Patent 10,653,656: Tretinoin Lotion Claims, Scope, Expiration Risk, and Patent Landscape

US Patent No. 10,653,656 protects a specific low-dose tretinoin lotion architecture, not tretinoin generally. Its commercial relevance is tied to a formulation containing 0.05% tretinoin, carbomer copolymer type B, carbomer homopolymer type A, soluble collagen, sodium hyaluronate, mineral oil, water, and optional excipients. The broadest independent claim also requires defined concentration ranges for the active agent, emulsifier, thickener, moisturizer, and oil phase.

The patent therefore creates a formulation-based barrier against products that reproduce the claimed excipient system, even if they use the same active ingredient and strength. A generic tretinoin product can potentially avoid infringement by changing the lotion structure, polymer system, moisturizer package, oil phase, or quantitative ranges.

What does US Patent 10,653,656 cover?

The patent covers topical tretinoin lotions for treating skin conditions, including acne vulgaris. Claim 1 requires all of the following:

Claim element	Required limitation
Dosage form	Topical lotion
Active agent	Tretinoin only
Tretinoin concentration	0.01% to 1% by weight
Polymeric emulsifier	Cross-linked copolymer of acrylic acid and C10-C30 alkyl acrylate
Emulsifier concentration	0.02% to 0.08%
Viscosity agent	Cross-linked acrylic-acid homopolymer
Viscosity-agent concentration	0.1% to 2%
Moisturizer	Soluble collagen and sodium hyaluronate
Moisturizer concentration	5% to 10%
Oil phase	One or more specified oils
Oil concentration	1% to 3.5%
Continuous phase	Water

The claim is composition-focused. It does not require a particular container, package size, manufacturing process, particle size, release profile, or clinical outcome.

The patent has three important claim groups:

Broad composition claims, principally claims 1-15.
Kit and treatment-method claims, principally claims 16-19.
A narrower composition and acne-treatment pair, claims 20-21.

How broad is claim 1 of US 10,653,656?

Claim 1 is materially narrower than a claim to “a topical tretinoin composition.” It requires a combination of structural ingredients and numerical ranges.

The active-agent limitation is relatively broad because it allows 0.01% to 1% tretinoin. The excipient limitations are more restrictive. A competing product must contain:

A C10-C30 alkyl acrylate/acrylic-acid copolymer of the claimed type;
A cross-linked acrylic-acid homopolymer;
Both soluble collagen and sodium hyaluronate;
An oil phase within the specified range;
A lotion dosage form.

A product containing tretinoin, glycerin, mineral oil, and carbomer may not infringe claim 1 if it lacks either soluble collagen or sodium hyaluronate. Conversely, changing only a nonessential excipient may not avoid infringement if all required claim elements remain present.

Literal infringement analysis

Literal infringement generally requires that the accused composition contain every limitation of the asserted claim. For claim 1, the following design-around variables are significant:

Design-around variable	Potential effect
Replace soluble collagen	May avoid claim 1 and claim 20
Replace sodium hyaluronate	May avoid claim 1 and claim 20
Use a different emulsifier	May avoid claim 1
Use a non-cross-linked thickener	May avoid claim 1
Change oil concentration below 1% or above 3.5%	May avoid claim 1
Use a non-lotion dosage form	May avoid composition claims requiring a lotion
Substitute a retinoid for tretinoin	May avoid claims requiring tretinoin
Use a different viscosity profile	May avoid dependent viscosity claims, but not necessarily claim 1
Omit mineral oil in a claim-13/20 configuration	May avoid those narrower claims

The doctrine of equivalents could create additional risk where a substituted ingredient performs substantially the same function in substantially the same way to achieve substantially the same result. The practical strength of that theory depends on the prosecution history, claim amendments, specification disclosures, and any argument-based estoppel.

Which claims are strongest for enforcement?

Claim 1

Claim 1 is the principal platform claim. It captures a family of tretinoin lotions with:

0.01%-1% tretinoin;
Two distinct acrylic polymer systems;
Collagen and sodium hyaluronate;
A specified oil phase;
Water.

Its breadth is reduced by the requirement that the composition include both the moisturizer combination and the two polymer categories.

Claims 2-12

These claims add individual commercial and formulation limitations:

Claim 2 narrows tretinoin to 0.05%.
Claim 3 specifies carbomer copolymer type B.
Claims 4 and 5 narrow the oil phase to mineral oil, light mineral oil, petrolatum, or combinations.
Claim 6 specifies carbomer homopolymer type A.
Claims 7 and 8 address thickener concentration, including 0.6%-1%.
Claims 9, 10, 14, and 15 cover viscosity ranges, with 8,000-12,000 cP being the principal narrower range.
Claim 12 requires pH maintenance at pH 5-6.

Claims 3, 5, 6, 8, 10, and 15 are commercially important because they track a plausible marketed product specification more closely than claim 1.

Claim 13

Claim 13 is the most formulation-specific claim. It requires or permits a composition including:

0.05% tretinoin;
0.05% carbomer copolymer type B;
0.6%-1% carbomer homopolymer type A;
5%-10% soluble collagen and sodium hyaluronate;
Up to 3% mineral oil;
5%-20% glycerin;
0.1%-2% butylated hydroxytoluene;
0.05%-0.5% octoxynol-9;
Optional benzyl alcohol and/or methylparaben;
Optional trolamine.

This claim is narrower but potentially stronger against a product that matches the disclosed commercial formulation. Its optional limitations require careful construction. An accused product may infringe if it includes the mandatory elements and does not need to include every optional element.

Claims 16-19

These claims extend protection to:

A kit containing the composition;
A treatment method;
Treatment of acne vulgaris;
Once-daily application.

Method claims can create additional exposure where a generic label instructs once-daily use for acne. A generic manufacturer may face induced-infringement risk if its labeling actively encourages the patented method, even if the composition itself is designed around a non-infringing formulation.

Claims 20 and 21

Claims 20 and 21 form a second independent composition and method pair. Claim 20 requires:

0.05% tretinoin;
0.04%-0.06% carbomer copolymer type B;
0.2%-1% carbomer homopolymer type A;
5%-10% soluble collagen and sodium hyaluronate;
Up to 3% mineral oil;
Water;
One or more listed categories of additional excipients.

Claim 21 covers applying that composition to treat acne vulgaris.

Claim 20 is narrower than claim 1 for polymer and active-agent concentrations, but it may be more closely aligned with a commercial formulation. Its lower polymer ranges could capture products that fall outside some dependent claims while remaining within the independent claim.

What formulation is associated with US 10,653,656?

The claim structure is consistent with a 0.05% tretinoin lotion product using a polymer-based emulsion system and moisturizing ingredients. The commercial formulation most closely associated with this patent is Altreno lotion, marketed for acne vulgaris by Ortho Dermatologics, a dermatology business associated with Bausch Health.

The claimed formulation differs from conventional tretinoin creams and gels in several ways:

Feature	Conventional tretinoin products	Claimed formulation
Dosage form	Cream, gel, solution, microsphere gel	Lotion
Active	Often 0.025%, 0.05%, or 0.1% tretinoin	Broadly 0.01%-1%; preferred 0.05%
Polymer system	Product-dependent	Carbomer copolymer plus carbomer homopolymer
Moisturization	Product-dependent	Soluble collagen plus sodium hyaluronate
Oil phase	Product-dependent	Specified oil classes and concentration
Viscosity	Product-dependent	Claims include 2,500-18,000 cP and 8,000-12,000 cP
Administration	Product-dependent	Once-daily acne treatment expressly claimed

The formulation claims do not cover all tretinoin lotions. They require the particular ingredient categories and ranges recited in the claims.

What is the FDA and Orange Book status of the product?

The FDA approved Altreno lotion, 0.05% tretinoin, for the topical treatment of acne vulgaris in patients 9 years of age and older on October 26, 2018. The product is associated with NDA 209475.[1]

Tretinoin is an established active ingredient with multiple approved topical products. The regulatory exclusivity value of a new tretinoin lotion therefore arises primarily from the formulation, product-specific approval, patent listings, and any applicable pediatric or other statutory exclusivity, rather than from new-chemical-entity exclusivity.

The Orange Book analysis should distinguish:

NDA approval status;
Listed patents;
Patent-use codes;
Any pediatric exclusivity;
The current listed patent expiration;
Whether the patent is listed against the approved product or a related presentation.

The supplied claim text establishes the patent’s formulation and method scope, but it does not establish the patent’s current Orange Book listing, use code, or live expiration status. Those items require a current FDA Orange Book and USPTO record.

When does US Patent 10,653,656 expire?

US Patent 10,653,656 issued on May 19, 2020. Its effective expiration date cannot be determined from the claims alone. The legally operative term may depend on:

The earliest effective nonprovisional or PCT filing date;
Patent-term adjustment;
Patent-term extension;
Terminal disclaimer;
Any disclaimer recorded against a related patent;
PTA calculation in the issued patent;
Applicable twenty-year term rules.

The patent should therefore be assessed using the USPTO patent-term data and the issued patent’s front-page term information rather than an estimated date. The issue date is not the expiration date.

What Paragraph IV challenges could affect the patent?

An ANDA applicant seeking approval for a generic equivalent of a 0.05% tretinoin lotion could make one or more certifications under Hatch-Waxman:

Certification	Commercial significance
Paragraph I	No patent information is listed
Paragraph II	Listed patent has expired
Paragraph III	Applicant will wait until patent expiration
Paragraph IV	Patent is invalid, unenforceable, or will not be infringed
Section viii statement	Applicant omits a patented method of use, where permitted

For this patent, a Paragraph IV strategy could attack:

Anticipation by an earlier tretinoin lotion formulation.
Obviousness based on combining known tretinoin vehicles, carbomers, humectants, and moisturizers.
Lack of written description for the full numerical ranges or ingredient combinations.
Lack of enablement across the full scope of claim 1.
Indefiniteness in terms such as “lotion,” “soluble collagen,” or polymer classifications.
Noninfringement based on a different polymer type, moisturizer, oil range, or dosage form.
Patent-term or listing defects under the Orange Book framework.

The most credible noninfringement path is usually formulation redesign. The most important invalidity evidence would include prepriority tretinoin lotion references disclosing the same dual-carbomer system and collagen/hyaluronate combination.

Are biosimilars relevant to this patent?

No. Biosimilar regulation under the Public Health Service Act does not apply to tretinoin, which is a small-molecule active ingredient. The relevant competitive pathway is an ANDA for a generic drug under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

A generic applicant would need to address the reference listed drug’s dosage form, strength, route of administration, active ingredient, labeling, and applicable pharmaceutical-equivalence requirements. Patent exposure would be analyzed separately through Paragraph IV or section viii certifications.

What other patents may surround the product?

The relevant patent landscape is likely to include several layers:

Formulation patents

These cover the lotion vehicle, polymer system, moisturizing combination, viscosity, pH, oil phase, and preservative package. US 10,653,656 is principally in this category.

Method-of-use patents

These cover treatment of acne vulgaris, patient age groups, dosing frequency, application regimens, or specific skin conditions. Claims 17-19 and 21 are method-of-use claims within this patent.

Manufacturing patents

Potential manufacturing barriers may involve:

Polymer hydration and neutralization;
Tretinoin dispersion;
Protection from light and oxygen;
Control of viscosity;
Order of ingredient addition;
Homogenization and emulsion formation;
Filling into opaque or air-restrictive packaging.

The supplied claims do not expressly require a manufacturing process. A competing manufacturer could use a different process and still infringe the composition claims if the final product meets every limitation.

Packaging and device patents

Airless pumps, opaque containers, metered-dose dispensers, and package compatibility may be protected separately. Those rights are not established by US 10,653,656.

Geographic coverage

A US patent provides enforceable rights in the United States and, subject to applicable doctrines, certain US territories. Parallel protection would require separate patents in other jurisdictions. A US claim does not establish protection in Canada, Europe, Japan, China, or other markets.

How strong is the patent estate?

The patent has moderate formulation strength and narrower blocking power than a broad claim to tretinoin topical products.

Strength factor	Assessment
Active ingredient	Weak as a standalone barrier because tretinoin is old
Dosage form	Moderate; lotion requirement excludes creams and gels
Excipient combination	Stronger; collagen plus sodium hyaluronate narrows design space
Polymer system	Moderate to strong if the commercial product uses both claimed carbomer types
Numerical ranges	Useful for targeting commercial formulations, but create invalidity and noninfringement boundaries
Method claims	Moderate, particularly where once-daily acne labeling is used
Manufacturing protection	Limited under the supplied claims
Biosimilar protection	Not relevant
Generic vulnerability	Meaningful if a redesigned lotion omits a required polymer or moisturizer

The patent is most valuable against a generic that copies the reference product’s formulation. It is less effective against a generic that uses a different lotion architecture, such as a non-carbomer thickener, alternative moisturizer system, different oil phase, or different dosage form.

What generic launch scenarios exist?

Scenario 1: Paragraph III delay

The applicant accepts the patent and delays launch until the relevant patent term ends. This reduces litigation cost but postpones market entry.

Scenario 2: Paragraph IV noninfringement

The applicant develops a lotion with tretinoin but omits soluble collagen, sodium hyaluronate, one of the claimed carbomer categories, or the claimed oil range. This approach targets the composition claims directly.

Scenario 3: Paragraph IV invalidity challenge

The applicant argues that the claimed combination would have been obvious from prior tretinoin vehicles and conventional carbomer lotion technology. The quality of the specification and prosecution history would be central.

Scenario 4: Section viii carve-out

If the only relevant listed claims are method-of-use claims and the FDA permits a labeling carve-out, the applicant could omit the patented acne use. This route is less useful if the patent is listed for the composition itself.

Scenario 5: At-risk launch

A company launches before final resolution after receiving FDA approval or otherwise determining that the litigation risk is acceptable. This exposes the company to damages and potential injunctive relief if infringement is established.

What patent litigation and settlements affect US 10,653,656?

The supplied information does not establish a current infringement action, Paragraph IV notice, settlement agreement, consent judgment, or appellate decision involving US 10,653,656. Those records must be confirmed through PACER, district-court dockets, Federal Circuit decisions, FDA Paragraph IV litigation records, and the Orange Book.

The absence of litigation information in the supplied record should not be treated as evidence that no case or settlement exists. Patent status is dynamic, particularly when an ANDA applicant files a Paragraph IV certification after the patent is listed.

Key Takeaways

US 10,653,656 is a formulation patent for tretinoin lotion, not a broad patent on tretinoin.
The principal protected architecture combines tretinoin, two acrylic polymer systems, soluble collagen, sodium hyaluronate, a defined oil phase, and water.
Claims 13, 20, and 21 are particularly relevant to a commercial 0.05% tretinoin lotion.
The patent’s strongest practical use is against a generic that copies the reference product’s excipient system.
A generic can reduce risk by changing the moisturizer combination, polymer system, oil range, dosage form, or other required formulation element.
Biosimilar competition is not relevant because tretinoin is a small molecule.
FDA approval of the associated 0.05% lotion does not by itself establish the patent’s current Orange Book listing or remaining term.
The exact expiration date, listing status, Paragraph IV activity, and litigation history require current USPTO, FDA, and court-record verification.

FAQs

Does US Patent 10,653,656 cover all 0.05% tretinoin products?

No. The claims require additional formulation elements, including specified carbomer polymers and soluble collagen plus sodium hyaluronate.

Can a generic use tretinoin with mineral oil and avoid the patent?

Potentially. Mineral oil alone is not enough to establish infringement. The generic would need to evaluate the polymer, moisturizer, concentration, dosage-form, and other limitations in each asserted claim.

Does changing the product from a lotion to a cream avoid the patent?

It may avoid claims expressly requiring a lotion, but the answer depends on claim construction and whether the accused product is legally characterized as a lotion despite its commercial labeling.

Is Altreno protected by a biologic patent or biosimilar exclusivity?

No. Altreno contains tretinoin, a small-molecule active ingredient. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway.

Does once-daily acne labeling create method-patent risk?

Yes. Claims 19 and 21 expressly address once-daily or acne-vulgaris treatment. A generic label that instructs the patented use can create method-of-use exposure even if the formulation issue is separately contested.

References

U.S. Food and Drug Administration. (2018). Altreno (tretinoin) lotion, 0.05%: NDA 209475 approval materials. FDA.
United States Patent and Trademark Office. (2020). U.S. Patent No. 10,653,656, topical pharmaceutical composition claims. USPTO.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
United States Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
U.S. Food and Drug Administration. (2024). Approved drug products and patent certification requirements under the Hatch-Waxman framework. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Dow Pharm	ALTRENO	tretinoin	LOTION;TOPICAL	209353-001	Aug 23, 2018		RX	Yes	Yes	10,653,656	⤷ Start Trial	Y			TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	114730	⤷ Start Trial
Brazil	112020020431	⤷ Start Trial
Canada	3095937	⤷ Start Trial
European Patent Office	3773641	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 10,653,656